Migraine headache: Options for acute treatment

Current Neurology and Neuroscience Reports

Volumn 5, Issue 2, 2005, Pages 86-92

  Taylor, Frederick R ^a  

^a PARK NICOLLET INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; ANTIMIGRAINE AGENT; ASPARTAME; BENZODIAZEPINE DERIVATIVE; BUTALBITAL; CAFFEINE; DECONGESTIVE AGENT; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE TARTRATE; FROVATRIPTAN; ISOMETHEPTENE; KETAMINE; KETOROLAC; NARATRIPTAN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; RIZATRIPTAN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; ZOLMITRIPTAN;

ALLODYNIA; ANALGESIA; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISABILITY; DISEASE DURATION; DOCTOR PATIENT RELATION; DRUG ABSORPTION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MIGRAINE; MIGRAINE AURA; NEPHROTOXICITY; REVIEW; THORAX DISEASE; TRUST;

EID: 17044438100     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-005-0004-5     Document Type: Review

References (48)

1. The International Classification of Headache Disorders. 2nd Edition: Headache Classification Subcommittee of the International Headache Society. Cephalalgia 2004, 24(Suppl 1):24-36.
2. Holroyd KA, Malinoski P, Davis MK, et al.: The three dimensions of headache impact: pain, disability and affective distress. Pain 1999, 83:571-578.
3. Lipton RB, Dodick D, Sadovsky R: A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 2003, 61:375-382.
4. Lipton RB, Diamond S, Reed M, et al.: Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001, 41:638-645.
5. Lipton RB, Cady RK, Stewart WF, et al.: Diagnostic lessons from the Spectrum Study. Neurology 2002, 58: 27-S31.
6. Stewart WF, Lipton RB, Kolodner K, et al.: Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 2003, 43: 58-265.
7. Ware JE, Bjorner JB, Dahlof C, et al.: Development for the headache impact test (HIT) using item response theory (IRT) [abstract]. Cephalalgia 2000, 20:309.
8. Maizels M, Burchette R: Rapid and sensitive paradigm for screening patients with headache in primary care settings. Headache 2003, 43:441-450.
9. Dowson AJ, Lipscombe S, Sender J, et al.: New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002, 18:414-39.
10. Dowson AJ, Sender J, Lipscombe S, et al.: Establishing principles for migraine management in primary care. Int J Clin Pract 2003, 57:493-507.
11. Ferrari MD, Roon KI, Lipton RB, et al.: Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668-1675.
12. Lipton RB, Stewart WF, Cady RK, et al.: Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000, 40:783-791.
13. Cady RK, Lipton RB, Hall C, et al.: Treatment of mild headache in disabled headache sufferers: results of the spectrum study. Headache 2000, 40:792-797.
14. Cady RK, Sheftell F, Lipton RB, et al.: Early treatment with sumatriptan enhances pain-free responses: retrospective analysis from three clinical trials. Clin Ther 2000, 22: 035-1048.
15. Pascual J, Cabarrocas X: Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002, 42910:28-31.
16. Living E: On Megrim, Sick-Headache, and Some Allied Disorders. A Contribution to the Pathology of Nerve Storms (1873). Nijmegen, The Netherlands: Arts & Boeve Publishers; 1997.
17. Wolff HG: Hedache and Other Head Pain, edn 2. New York: Oxford University Press; 1963.
18. Burstein R, Yarnitsky D, Boor-Arych I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614-624.
19. Burstein R, Yarnitsky D: The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000, 123 (Pt 8):1703-1709.
20. Burstein R, Collins B, Jakubowski M: Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004, 55:19-26.
21. Burstein R, Jakubowski M: Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004, 55:27-36.
22. Headache Consortium US: American Academy of Neurology Headache Guidelines. Available at http://www.aan.com/professionals/practiceguidelines/index.cfm. Accessed October 15, 2004.
23. Snow V, Weiss K, Wall EM, Mottur-Pilson C, for the American Academy of Family Physicians and the American College of Physicians - American Society of Internal Medicine: Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002, 37:840-849.
24. Bedell AW, Cady RK, Diamond ML, et al.: Patient-centered Strategies for Effective Management of Migraine. Primary Care Network; 2000.
25. Taylor F, Hutchinson S, Graff-Radford S, et al.: Making the diagnosis and management of migraine relevant in the primary care setting. J Fam Pract 2004, (Suppl):S3-S24.
26. Lipton RB, Stewart WF, Stone AM, et al.: Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) study: a randomized trial. JAMA 2000, 284: 599-2605.
27. Lolland JH, Kim SS, Betenhorst AS, et al.: Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001, 76:1093-1101.
28. Halpern MT, Lipton RB, Cady RK, et al.: Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache 2002, 42:984-999.
29. Goadsby P: Post triptan era for the treatment of acute migraine. Curr Pain Headache Rep 2004, 8:393-398.
30. Lipton RB, Raskin N, Ruoff G, et al.: Over-the-counter analgesics and kidney disease. Am J Kidney Dis 1996, 27:917-918.
31. Dodick D, Lipton RB, Martin V, et al.: Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004, 44: 14-425.
32. Tepper SJ, Millson D: Safety profile of the triptans. Expert Opin Drug Safe 2003, 2:123-132.
33. Dodick DW, Martin VT, Smith T, Silberstein S: Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004, 44(Suppl 1):S20-S30.
34. The International Classification of Headache Disorders. 2nd Edition. Headache Classification Subcommittee of the International Headache Society. Cephalalgia 2004, 24 (Suppl 1):94-97.
35. Rapoport AM, Tepper SJ: Triptans are all different. Arch Neurol 2001, 58:1479-1480.
36. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD: The triptan formulations: how to match patients and products. CNS Drugs 2003, 17:431-447.
37. Sheftell FD, Feleppa M, Tepper SJ, et al.: Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 2004, 44:661-668.
38. Dowson AJ, Tepper SJ, Baos V, et al.: Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin 2004, 20:1125-1135.
39. Fox AW, Davis RL: Migraine chronobiology. Headache 1998, 38:436-441.
40. Geraud G, Keywood C, Senard JM: Migrane headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003, 43: 76-388.
41. Dodick DW, Lipton RB, Ferrari MD, et al.: Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR project. Curr Pain Headache Rep 2004, 8:435-442.
42. Dodick DW, Martin V: Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004, 24:417-424.
43. Tepper S, Allen C, Sanders D, et al.: Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 2003, 43:44-48.
44. Saper J: What matters is not the differences between triptans, but the differences between patients. Arch Neurol 2001, 58:1481-1482.
45. Luciani R, Carter D, Mannix L, et al.: Prevention of migraine during prodrome with naratriptan. Cephalalgia 2000, 20:122-126.
46. Kaube H: Ketamine is effective in aborting aura [abstract]. Presented at Headache World 2000, London, September 3-7, 2000.
47. Lake AE 3rd: Behavioral and nonpharmacologic treatments of headache. Med Clin North Am 2001, 85:1055-1075.
48. Mauskop A: Alternative therapies in headache. Is there a role? Med Clin North Am 2001, 85:1077-1084.